Catalyst

Slingshot members are tracking this event:

Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CERC

100%

Additional Information

Additional Relevant Details The Pharmacotherapies for Alcohol and Substance Use Disorders (PASA) Consortium has provided a grant to Dr. Colin Haile (Principal Investigator, University of Houston), Dr. Therese Kosten(Co-Investigator, University of Houston) and Dr. Ronald Marcus (Co-Investigator, Cerecor) to assess the efficacy of CERC-501, a selective kappa opioid receptor (KOR) antagonist, separately and in combination with one of two anti-hypertensive drugs (both of which target norepinephrine), in reducing post-traumatic stress disorder (PTSD)-induced alcohol use disorder (AUD) in animal models. This study is a collaborative effort between Cerecor and Drs. Haile and Kosten, who are both established experts in behavioral neuroscience, and will be conducted at the University of Houston.
http://ir.cerecor.co...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 25, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Co-morbid, Cerc-501, Norepinephrine